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Key findings 
 
1. People with problematic substance use and end of life care needs cannot 
currently be directly identified in any single health or population database or 
dataset.  
2. Using freely available data, such target cases can only be estimated using 
proxy variables such as disease type, cause of death and place of death. This 
presents sensitivity and specificity problems for identification of all cases 
(sensitivity) and excludes non-cases (specificity).  
3. Data from the Office for National Statistics and Hospital Episode Statistics 
are currently the most reliable sources of freely available data from which to 
identify and calculate prevalence and incidence of end of life care for people 
with substance use problems, using cause of death and treatment episodes 
as indirect indicators of cases.  
4. Other direct sources of medical diagnostic data for this target population 
stem from end of life care records but these are currently poorly reported 
and do not facilitate accurate surveillance or monitoring.  
5. Reliance on medically determined diagnoses and cause of death excludes 
target cases where their end of life care need is unrelated or only indirectly 
related to substance use.  
6. People with problematic alcohol use may be easier to identify via morbidity 
and mortality diagnoses than people with problematic illicit drug use. This is 
because there is a narrower range of chronic diseases associated with alcohol 
use than drug use.  
7. For people with problematic illicit drug use, existing data relating to disease 
type are not useful for case identification because of the wide range of 
diseases associated with illicit drug use. As there is no ‘typical’ disease 
profile, it is not possible to extract these cases from others in which there is 
no illicit drug use (decreased specificity).  
8. Databases monitoring problematic illicit drug users receiving treatment for 
their substance use only identify cases within drug treatment services, and 
only record their substance use treatment and reason for treatment exit, 
such as ‘died’. Therefore, end of life care is not traceable via these 
databases, and such databases will not record people with problematic illicit 
drug use who do not use treatment services.  
9. To obtain more accurate and reliable prevalence and incidence of end of life 
care for people with problematic substance use it will be necessary to 
combine existing datasets and access patient records.  
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Background 
 
Public Health England states that life expectancy has increased in the last 30 
years for older adults (at ages 65, 75, 85 and 95) and continues to rise 
incrementally for both genders (PHE, 2016a). At the same time, the 
demographic age profile of the UK is changing, with a disproportionate growth 
of people over 65 (Dixon et al., 2015). This ageing profile is mirrored in the 
population of drug users in the UK. According to Beynon and Lawson, (2010), 
evidence from sources such as the National Drug Treatment Monitoring System 
(NDTMS) and the British Crime Survey indicates that the average age of drug 
users accessing treatment is rising, with higher proportions of treatment 
admissions for people over 40. This is likely to be explained by the reduction in 
younger people using drugs and needing treatment, and the cohort of users 
from the 1980s and 1990s surviving into older age. Among alcohol users, while 
the estimates for rates of alcohol use among young people have started to 
reduce (NHS Digital, 2015), older people still drink more frequently than 
younger people (Fuller, 2015) and alcohol is currently among the top three 
lifestyle risk factors of death, contributing 10% of the burden of disease and 
death in the UK (Baker, House of Commons Health Committee, 2017). 
 
Methodology 
 
The aims of this scoping study were to:  
i. Identify key sources of quantitative data on prevalence and incidence of 
end of life care delivered to people with problematic substance use; 
ii. Identify end of life care needs for people with problematic substance use;  
iii. Identify the prevalence and incidence of people with co-existing 
problematic substance use and end of life/palliative care needs.  
 
The main objectives were to:  
i. Identify and appraise key sources of patient data indicative of end of life 
treatment received and disease type;  
ii. Identify and appraise key data sources of end of life care delivery;  
iii. Identify key sources of care delivery to people with substance use 
morbidity;  
iv. Critically analyse the value of the data, relating to end of life care and 
substance user care needs and identify anomalies and gaps in the 
evidence;  
v. Identify possible service gaps that indicate poor access or uptake of end 
of life care for people with substance use problems;  
vi. Make recommendations for the improvement of data collection and 
availability;  
vii. Make specific recommendations for more detailed interrogation of existing 
data.  
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This investigation focused on freely available data which typically exist from 
single sources such as the Office for National Statistics (ONS) or Hospital 
Episode Statistics (HES). Where analysis of existing data has already been 
performed and reported by third parties, these findings have been included in 
this reporting. For example, The National End of Life Care Intelligence Network 
has performed an analysis of liver disease deaths based on ONS data (Effiong et 
al., 2012), and their findings are incorporated into this report.  
 
This exploration and analysis followed a five-stage strategy as follows:  
 
Stage 1.   A broad search for all relevant sources of primary data and available 
reports based on primary or secondary data.  
Stage 2.  Appraised potential sources for relevance to the study and 
evaluated their quality and type of data. 
Stage 3.  Key sources of data were identified for inclusion. The exclusion 
criteria was a lack of identification of patients with substance use 
problems for whom end of life care was an identified need (target 
cases). 
Stage 4.  Interrogation of the data.    
Stage 5.  Analysis and evaluation of findings.  
 
Findings 
 
Aim 1: Identify key sources of quantitative data on prevalence and 
incidence of end of life care for people who have problematic substance use.  
 
No whole-population datasets directly identify people with problematic 
substance use and end of life care needs. The most useful data source to 
identify possible cases are cause of death records from the Office for National 
Statistics (ONS), and deaths and treatment episodes from the Hospital Episode 
Statistics (HES).  
 
Hospital Episode Statistics currently include two indicators of palliative care 
delivery in hospital which are then reported to the Health and Social Care 
Information Centre (HSCIC). Palliative Care treatment episodes recorded by 
HES give a breakdown of finished consultant episodes by basic patient details 
(sex, age, length of stay).  
 
 
The Office for National Statistics uses the International Classification of Diseases 
10 (ICD-10) to define an alcohol-related death. These are medically-determined 
diagnoses which are recorded as the underlying cause of death where alcohol is 
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regarded as the direct or underlying cause. These are mostly chronic diseases 
and conditions, reported using 4-character ICD-10 coding. 
 
The ONS definition of a drug misuse-related death is where drug use or 
dependence is the underlying cause or where drug poisoning is the underlying 
cause of death (ONS, 2015). ‘Drug’ is defined as a substance controlled under 
the Misuse of Drugs Act 1971. These data only record acute deaths directly 
attributable to drug use (such as overdose). This data does not capture chronic 
deaths indirectly associated with drug misuse.  
 
The National Drug Treatment Monitoring System (NDTMS) collects data on 
structured substance use treatment provided by substance use treatment 
service providers. The National Drug Evidence Centre collates these data on 
behalf of Public Health England. This data only captures patients receiving drug 
or alcohol treatment. It does not record deaths or palliative care treatment.  
 
Data on end of life care are collected by the ONS and HES. Both inform Public 
Health England and the National End of Life Care Intelligence Network 
(NEoLCIN). Public Health England aggregate mortality cause into only three 
categories: cancer, respiratory and circulatory. This does not allow identification 
of cases of patients with problematic substance use directly or indirectly via 
proxy variables of disease type. 
 
The Minimum Dataset (MDS), produced by the National Council for Palliative 
Care (NCPC) and PHE, collates end of life and palliative care data from providers 
in the statutory, private and voluntary sector. However, the most recent report 
(NCPC, 2016a) on the MDS states that the current reporting rate at 66% of all 
services is neither consistent across the country, nor across service types. MDS 
provides a good record of hospice provision but misses a large proportion of 
patients receiving end of life care in hospital settings. Data collected only 
relates to demographics and primary diagnosis. Therefore, there is no clear 
indicator of patients who may have problematic substance use. The MDS is 
being discontinued.  
 
The EPaCCS report (The Whole System Partnership, 2016) evaluates the 
EPaCCS system using qualitative and quantitative sources including ONS place 
of death records, HES and the EPaCCS’ own in-depth interviews. EPaCCs may 
offer a source of evidence for local and regional monitoring of end of life care. 
However, this does not appear to differ significantly from data which are already 
available via ONS and HES. 
 
The Palliative Care Registers record primary care patients who are recognised 
by the general practitioner as requiring end of life care in their last year of life. 
The Palliative Care Register system and the palliative care coding for hospitals 
are recorded inconsistently across services, with many categories open to 
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interpretation. This resource is demonstrating clinical improvements but is 
criticised as an audit tool as it relies on medical recognition of cases 
 
Audit data are collected periodically from HES and the National Cancer Audit. 
Register on specific cancer types, treatment interventions, incidence, 
prevalence and care pathways. Current audits do not report end of life or 
palliative care consistently. Only the Head and Neck Cancer Audit reports the 
treatment and care incidence as a percentage of treatment incidents overall. 
There is no breakdown of diagnoses, causes of death or co-morbidities which 
would aid identification of cases. 
 
Other disease types that present occasional audit for this patient group will be 
respiratory diseases and liver diseases. 
 
In summary, appraisal of existing data found that no directly accessible sources 
are available that gives direct information on people with problematic substance 
use and their use of and access to end of life care. Proxy variables of disease 
type give some indication of proportions of people who may have alcohol-
related diseases such as liver disease. Data relating to cancers generally, or 
cancers with a higher relation to alcohol or drug use than others, lack the 
evidence to make any calculations of estimates currently. People with drug-
related terminal illnesses are not traceable via proxy variables as the disease 
types are too varied to identify cases. Specific data from end of life sources lack 
the detail to identify cases and is poorly reported, with a bias towards hospice 
care. 
 
Aim 2: Identify end of life care needs of people with substance use problems 
For people with substance use problems at end of life, the nature of the 
diseases typically faced by the majority may present a degree of 
unpredictability and complexity that makes care planning and delivery for end 
of life difficult for services more commonly equipped to manage cancer patients.  
 
Data relating to palliative and end of life care services indicate that almost 80% 
of people accessing inpatient care have a cancer diagnosis, either seen as day 
care, community care, hospital support or outpatients. The greatest number of 
non-cancer diagnoses patients are reportedly seen for hospital support. 
 
Disease type: 
ONS (2016b) data on cause of death indicate that alcohol was partly 
attributable to death in 1.2% of all deaths in 2014. Most of these deaths were a 
result of ischaemic heart disease (38.5%) or liver cancer (26.9%). The 
likelihood of having an alcohol-related condition is higher among those who die 
from liver cancer than ischaemic heart disease (1.0%). Among people who die 
from mouth and throat cancers, alcohol is recorded as a contributory factor in 
2.2% of deaths, and other cardiovascular diseases (hypertensive diseases, 
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ischemic stroke, haemorrhagic stroke) are linked to underlying alcohol use at 
1.4%, 1.0% and 0.9% respectively. 
 
Forty-one percent of hospital admissions for alcohol-related conditions for 
alcohol-related cancer occur amongst the lowest three socio-economic deciles, 
with a high proportion of these admitted for cancer of the larynx (48%), and 
cancer of the liver (41%). Of all alcohol-related liver disease admissions, 53% 
were from the lower three socio-economic groups according to Public Health 
England.  
 
Research evidence is needed to explore deaths among drug users beyond the 
acute deaths used by ONS and PHE to denote a drug-related death. Typical 
acute disease types that lead to mortality among drug users are found to be 
cellulitis, pneumonia, alcohol-related liver disorders (Beynon and Lawson, 2010; 
Stenbacka et al., 2010). Research findings indicate that that deaths often 
classified as non‐drug-related are likely to result from substance use - 
particularly infection.  
 
Key population findings indicate that drug users die at a younger age than the 
general population, and often include problematic alcohol use (Beynon et al., 
2010). The biggest cause of death among drug users is indicated to be 
cardiovascular disease, in line with the general population. Further evidence 
indicates that chronic terminal diseases for drug users were respiratory disease, 
circulatory disease and liver disease; all typically at a younger age than the 
general population.  Drug users may be more at risk of morbidities and 
mortality than the general population due to their history of drug use and 
associated lifestyle. 
 
In summary, people with substance use problems are as likely to die from 
cardiovascular disease as the general population, however, those with drug use 
histories are likely to die at a younger age.  
 
People with alcohol use disorders are more likely to die from liver diseases 
(including cancers) than the general population. People with drug use histories 
are also vulnerable to chronic liver or respiratory diseases, possibly due to their 
drug lifestyle.  Many of the diseases associated with substance use can be 
unpredictable in their progress (with the exception of cancers or dementia) and 
may explain why this population is more likely to receive end of life care in a 
hospital setting.  
 
Aim 3: Identify the prevalence and incidence of people with co-existing 
problematic substance use and end of life/palliative care needs 
Due to the lack of directly accessible data on end of life care for this patient 
group, it is not possible to identify the specific prevalence and incidence of 
people with problematic substance use and end of life care needs. However, the 
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data available indicates that, for people with certain disease conditions, hospice 
or planned end of life care is less likely to be available. Extrapolation of disease 
type associated with substance use, prevalence of substance use within the 
general population, and evidence from end of life care services, gives some 
indication of needs for this patient group.  
 
There were approximately 293,879 people aged 15-64 using opiates or crack 
cocaine in England, with 2.5/1,000 injecting drugs between these age ranges. 
These figures do not include adults over 64 years of age (PHE, 2013). 
 
Evidence from sources such as the National Drug Treatment Monitoring System 
(NDTMS) and the British Crime Survey indicates that the average age of drug 
users accessing treatment is rising, with higher proportions of treatment 
admissions for people over 40 (Beynon and Lawson, 2010). This is likely to be 
explained by the cohort of users from the 1980s and 1990s surviving into older 
age. Among alcohol users, older people still drink more frequently than younger 
people and alcohol is currently among the top three lifestyle risk factors of 
death, contributing 10% of the burden of disease and death in the UK.  
 
Approximately one per cent of the population in England and Wales die per 
year, equating to half a million deaths. The majority of deaths (85%) occur for 
people aged over 75. The main causes of death are cancer (28%) and 
circulatory diseases (26%) (ONS, 2016a). Just under half of deaths take place 
in hospital (48%), with roughly a quarter at home (23%), or in care homes 
(22%), and only about 6% of people die in a hospice (ONS, 2016a).  
 
Data from the Public Health England End of Life Care Profiles (2017) indicate 
that, in 2015, 46.7% of end of life care patients died in hospital, 5.6% died in a 
hospice, 22.8% died in their own home, 22.6% died in a care home, and 2.2% 
died in ‘other’ places (not specified).  
 
The data illustrate the spread of end of life care delivery at the point of death, 
and it is not to be assumed from this data that there is a difference in quality of 
care associated with different localities of death, as they may be explained 
equally as clinical need, preference or lack or resources, but the differences 
need to be explored in the light of concerns over disproportionate delivery of 
care in hospices to cancer patients. 
 
The 2013 Health Survey of England Palliative Care Services report identifies 
patients’ reasons for not receiving end of life care services were either that the 
person died in hospital (36.5% of all respondents) or that the death was sudden 
(27% of all respondents) (ONS, 2014a). Approximately 12.5% said the patient 
did not want end of life care; that end of life care was not available (12.5%); or 
that they did not know about the service (4%). This survey’s findings further 
illustrate, however, that specialist end of life care availability is heavily weighted 
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towards cancer cases and suggests that people with other illnesses are less 
likely to access specialist end of life care. 
 
Implications and recommendations 
 
Implications for practice 
Findings from end of life care services illustrate that specialist end of life care 
availability is weighted towards cancer cases and that people with other 
illnesses are less likely to access specialist end of life care. While this bias may 
be due to clinical reasons, it underlines the fact that people with cardiovascular 
and non-cancer liver diseases are less likely to receive end of life care. Chronic 
causes of death for people with problematic alcohol or drug problems is most 
likely to be cardiovascular or liver disease, therefore statistically, people with 
problematic substance use tend to have less access to specialist end of life care 
than people with a cancer diagnosis. The implications for practice are that 
specialist end of life care services need to develop the skills and resources to 
deliver care to patients with less predictable or more complex disease 
conditions.  
 
Recommendations for practice 
Greater capacity is required in specialist end of life care services for complex 
and less predictable end of life conditions.  
 
Implications for policy and service commissioning 
The Palliative Care Clinical Dataset commencing in 2017/18 may provide more 
detailed data on patients accessing specialist palliative services and enable 
some analysis of complexity of care or data linkage via NHS patient identifiers.  
 
The Palliative Care Register system and the palliative care coding for hospitals 
are recorded inconsistently across services, with many categories open to 
interpretation. Both systems need to be standardised for consistent data 
collection and accurate analysis across services.  
 
The TOPS recording tool for the reporting of patient treatment episodes in the 
NDTMS is not sensitive enough to identify co-morbidities. While there is a focus 
on mental health and blood borne viruses in the NDTMS, the inclusion of 
physical co-morbidities would enable improved health and wellbeing monitoring 
of patients receiving substance use treatment.  
 
The replacement of the MDS with the Palliative Care Clinical Dataset (PCCD) 
may facilitate data linkage between the PCCD and ONS, HES and CPRD data 
through use of patient NHS identifiers. Other data proposed for collection on the 
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PCCD does not appear to improve identification of co-morbidities or otherwise 
give the patient’s health history.  
 
Greater detail of patient demographics, social and medical history and co-
morbidities would enable more accurate audit of service access for end users. 
 
Recommendations for policy and service commissioning 
Improved monitoring and surveillance of service accessibility for disadvantaged 
patient groups will require more detailed and specific data collection at service 
delivery level. 
 
Implications for future research 
In order to obtain more accurate data on this population group it is 
recommended that direct access to datasets held by HES, ONS and GP records 
would enable more accurate identification of target cases. This may be achieved 
by: 
 
Use of existing data:  
Access HES palliative care (finished consultant episodes) data and link with ONS 
mortality data to obtain a measure of incidence of disease type and hospital 
provision of end of life care.  
 
Data linkage:  
Develop/use proxy variables to support the analysis of existing data. Conduct a 
review of links between diseases and substance use to obtain estimates on 
which to calculate sensitivity and specificity of proxy variables and produce 
estimates of incidence and prevalence.  
 
Direct access to patient records:  
Invest in data linkage and analysis between HES and ONS mortality data using 
the HESID index. Access to case identifiers (via patient records) removes the 
necessity of using proxy variables.  
Recommendations for future research 
Further research will require greater accessibility of data and capacity to 
combine datasets. 
 
Conclusion 
In the absence of systematic screening and recording of alcohol and drug use 
among all patients with end of life conditions, and the omission of end of life 
care or physical co-morbidity surveillance by substance use treatment services, 
it is not possible to determine accurately the scale of the end of life care need 
for people with alcohol or drug problems without more detailed data analysis.   
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A more accurate estimation of end of life care delivery to people with substance 
use problems can only be obtained if patients with problematic substance use 
can be identified with a high degree of accuracy. This requires routine collection 
and recording of patient histories that extends beyond the disease diagnosis 
related to their end of life care. These data are most likely to stem from 
services delivering end of life care at any stage of the process, therefore 
including primary care, hospitals and specialist palliative care services. In the 
meantime, a more accurate monitoring of end of life care delivery to these 
patient groups requires improved identification of cases using existing data. 
These data are currently collected in different monitoring systems which use 
different definitions of drug- or alcohol-related disease, direct causal links or 
indirect causes, and include cases either only by first disease type or where 
drugs or alcohol may be mentioned on medical certificates of cause of death. 
This means that data linkage requires compatibility in the first instance to 
permit merging of databases, or a degree of detail such as history of alcohol or 
drug use, or treatment for an alcohol or drug addiction. Estimates made for this 
report indicate that there is likely to be an operationalised discrimination 
against people with a history of substance use problems receiving end of life 
care in a timely manner. The evidence reviewed for this report indicates that 
this is likely to be due to the disease type and clinical presentation of these 
patients that results in a higher degree of hospital deaths among this 
population. The implication is that end of life and palliative care services are not 
currently equipped to manage the complex needs presented by this group of 
service users.  
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